 | • レポートコード：MRC2301E004 • 出版社/出版日：Persistence Market Research / 2022年10月19日 • レポート形態：英文、PDF、306ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,140,000 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,590,000 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料は、世界の多嚢胞性卵巣症候群（PCOS）治療市場について総合的・多面的に調査しています。本資料では、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症危機分析、需要分析・予測、治療薬クラス別（経口避妊薬、インスリン抵抗性改善薬、抗うつ剤、オルニチン脱炭酸酵素阻害剤、その他）分析、流通チャネル別（病院薬局、ドラッグストア/OTC、Eコマース、診療所）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ）分析、構造分析、競争分析などを整理しております。また、Novartis AG、Sanofi.、Teva Pharmaceutical Industries Limited、Merck & Co., Inc. (Merck group)、AstraZeneca plc、Bayer AG、Abbott、Pfizer, Inc.、Bristol-Myer Squibb Companyなどの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症危機分析 ・需要分析・予測 ・世界の多嚢胞性卵巣症候群（PCOS）治療市場規模：治療薬クラス別 - 経口避妊薬における市場規模 - インスリン抵抗性改善薬における市場規模 - 抗うつ剤における市場規模 - オルニチン脱炭酸酵素阻害剤における市場規模 - その他における市場規模 ・世界の多嚢胞性卵巣症候群（PCOS）治療市場規模：流通チャネル別 -病院薬局チャネルの市場規模 - ドラッグストア/OTCチャネルの市場規模 - Eコマースチャネルの市場規模 - 診療所チャネルの市場規模 ・世界の多嚢胞性卵巣症候群（PCOS）治療市場規模：地域別 - 北米の多嚢胞性卵巣症候群（PCOS）治療市場規模 - 中南米の多嚢胞性卵巣症候群（PCOS）治療市場規模 - ヨーロッパの多嚢胞性卵巣症候群（PCOS）治療市場規模 - 東アジアの多嚢胞性卵巣症候群（PCOS）治療市場規模 - 南アジアの多嚢胞性卵巣症候群（PCOS）治療市場規模 - オセアニアの多嚢胞性卵巣症候群（PCOS）治療市場規模 - 中東・アフリカの多嚢胞性卵巣症候群（PCOS）治療市場規模 ・構造分析 ・競争分析 |
Polycystic Ovary Syndrome (PCOS) Treatment Market: Scope of Report
The latest publication by Persistence Market Research on the global polycystic ovary syndrome (PCOS) treatment market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for polycystic ovary syndrome treatment market products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, product manufacturers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the polycystic ovary syndrome (PCOS) treatment market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the polycystic ovary syndrome treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the polycystic ovary syndrome treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the polycystic ovary syndrome treatment market offers information divided into three important segments – drug class and distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug Class
Oral Contraceptives
Insulin Sensitizing Agents
Antidepressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
Distribution Channel
Hospital Pharmacies
Drug Stores/OTC
e-Commerce
Clinics
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for PCOS treatment over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the polycystic ovary syndrome treatment market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the PCOS treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the PCOS treatment market are more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Regulatory Scenario
4.3. Go-To-Market Strategy
4.4. PESTLE Analysis
4.5. Porters Analysis
4.6. Supply Chain Analysis
4.7. Impact of PCOS on the Quality of Life in Women in correlation to Age, BMI, Education, Work Place as well as Pregnancy
4.8. A detailed Assessment of Healthcare Related Economic Burden of PCOS and Immediate & Long Term Impact
4.9. Polycystic Ovary Syndrome (PCOS) Treatment Market: Payer Mix Assessment
4.10. Treatment Options in Management of PCOS
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.2. Forecast Factors – Relevance & Impact
5.2.1. Increasing Uses of Epilatory Therapy
5.2.2. Growing Prevalence of PCOS
5.2.3. Growing number of Manufacturing Companies
5.2.4. Increasing awareness
5.2.5. Side Effects of Symptomatic Treatment Drugs
5.2.6. Strategic Mergers and Acquisitions Among Pharmaceutical Companies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. COVID19 and Impact Analysis
6.4. 2021 Market Scenario
6.5. Recovery Scenario – Short term, Midterm and Long Term Impact
7. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2015–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022–2032
8.3.1. Oral contraceptives
8.3.2. Insulin Sensitizing Agents
8.3.3. Anti-Depressants
8.3.4. Ornithine Decarboxylase Inhibitors
8.3.5. Aromatase Inhibitors
8.3.6. Diuretics
8.4. Market Attractiveness Analysis By Drug Class
9. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022–2032
9.3.1. Hospital pharmacies
9.3.2. Drug Stores/OTC
9.3.3. E-commerce
9.3.4. Clinics
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2015–2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug Class
11.4.3. By Distribution Channel
11.5. Drivers and Restraints – Impact Analysis
11.6. Country Level Analysis & Forecast
11.6.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market
11.6.1.1. Introduction
11.6.1.2. Market Analysis and Forecast by Market Taxonomy
11.6.1.2.1. By Drug Class
11.6.1.2.2. By Distribution Channel
11.6.2. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market
11.6.2.1. Introduction
11.6.2.2. Market Analysis and Forecast by Market Taxonomy
11.6.2.2.1. By Drug Class
11.6.2.2.2. By Distribution Channel
12. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Rest of Latin America
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Class
12.4.3. By Distribution Channel
12.5. Drivers and Restraints – Impact Analysis
12.6. Country Level Analysis & Forecast
12.6.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market
12.6.1.1. Introduction
12.6.1.2. Market Analysis and Forecast by Market Taxonomy
12.6.1.2.1. By Drug Class
12.6.1.2.2. By Distribution Channel
12.6.2. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market
12.6.2.1. Introduction
12.6.2.2. Market Analysis and Forecast by Market Taxonomy
12.6.2.2.1. By Drug Class
12.6.2.2.2. By Distribution Channel
12.6.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market
12.6.3.1. Introduction
12.6.3.2. Market Analysis and Forecast by Market Taxonomy
12.6.3.2.1. By Drug Class
12.6.3.2.2. By Distribution Channel
13. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Distribution Channel
13.5. Drivers and Restraints – Impact Analysis
13.6. Country Level Analysis & Forecast
13.6.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.1.1. Introduction
13.6.1.2. Market Analysis and Forecast by Market Taxonomy
13.6.1.2.1. By Drug Class
13.6.1.2.2. By Distribution Channel
13.6.2. France Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.2.1. Introduction
13.6.2.2. Market Analysis and Forecast by Market Taxonomy
13.6.2.2.1. By Drug Class
13.6.2.2.2. By Distribution Channel
13.6.3. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.3.1. Introduction
13.6.3.2. Market Analysis and Forecast by Market Taxonomy
13.6.3.2.1. By Drug Class
13.6.3.2.2. By Distribution Channel
13.6.4. Spain Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.4.1. Introduction
13.6.4.2. Market Analysis and Forecast by Market Taxonomy
13.6.4.2.1. By Drug Class
13.6.4.2.2. By Distribution Channel
13.6.5. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.5.1. Introduction
13.6.5.2. Market Analysis and Forecast by Market Taxonomy
13.6.5.2.1. By Drug Class
13.6.5.2.2. By Distribution Channel
13.6.6. Benelux Union Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.6.1. Introduction
13.6.6.2. Market Analysis and Forecast by Market Taxonomy
13.6.6.2.1. By Drug Class
13.6.6.2.2. By Distribution Channel
13.6.7. Nordic Countries Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.7.1. Introduction
13.6.7.2. Market Analysis and Forecast by Market Taxonomy
13.6.7.2.1. By Drug Class
13.6.7.2.2. By Distribution Channel
13.6.8. Switzerland Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.8.1. Introduction
13.6.8.2. Market Analysis and Forecast by Market Taxonomy
13.6.8.2.1. By Drug Class
13.6.8.2.2. By Distribution Channel
13.6.9. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market
13.6.9.1. Introduction
13.6.9.2. Market Analysis and Forecast by Market Taxonomy
13.6.9.2.1. By Drug Class
13.6.9.2.2. By Distribution Channel
14. South Asia Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Distribution Channel
14.5. Drivers and Restraints – Impact Analysis
14.6. Country Level Analysis & Forecast
14.6.1. India Polycystic Ovary Syndrome (PCOS) Treatment Market
14.6.1.1. Introduction
14.6.1.2. Market Analysis and Forecast by Market Taxonomy
14.6.1.2.1. By Drug Class
14.6.1.2.2. By Distribution Channel
14.6.2. Indonesia Polycystic Ovary Syndrome (PCOS) Treatment Market
14.6.2.1. Introduction
14.6.2.2. Market Analysis and Forecast by Market Taxonomy
14.6.2.2.1. By Drug Class
14.6.2.2.2. By Distribution Channel
14.6.3. Malaysia Polycystic Ovary Syndrome (PCOS) Treatment Market
14.6.3.1. Introduction
14.6.3.2. Market Analysis and Forecast by Market Taxonomy
14.6.3.2.1. By Drug Class
14.6.3.2.2. By Distribution Channel
14.6.4. Thailand Polycystic Ovary Syndrome (PCOS) Treatment Market
14.6.4.1. Introduction
14.6.4.2. Market Analysis and Forecast by Market Taxonomy
14.6.4.2.1. By Drug Class
14.6.4.2.2. By Distribution Channel
15. East Asia Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Class
15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Distribution Channel
15.5. Drivers and Restraints – Impact Analysis
15.6. Country Level Analysis & Forecast
15.6.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market
15.6.1.1. Introduction
15.6.1.2. Market Analysis and Forecast by Market Taxonomy
15.6.1.2.1. By Drug Class
15.6.1.2.2. By Distribution Channel
15.6.2. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market
15.6.2.1. Introduction
15.6.2.2. Market Analysis and Forecast by Market Taxonomy
15.6.2.2.1. By Drug Class
15.6.2.2.2. By Distribution Channel
15.6.3. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market
15.6.3.1. Introduction
15.6.3.2. Market Analysis and Forecast by Market Taxonomy
15.6.3.2.1. By Drug Class
15.6.3.2.2. By Distribution Channel
16. Oceania Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Class
16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Distribution Channel
16.5. Drivers and Restraints – Impact Analysis
16.5.1. By Country
16.5.2. By Drug Class
16.5.3. By Distribution Channel
16.6. Country Level Analysis & Forecast
16.6.1. Australia Polycystic Ovary Syndrome (PCOS) Treatment Market
16.6.1.1. Introduction
16.6.1.2. Market Analysis and Forecast by Market Taxonomy
16.6.1.2.1. By Drug Class
16.6.1.2.2. By Distribution Channel
16.6.2. New Zealand Polycystic Ovary Syndrome (PCOS) Treatment Market
16.6.2.1. Introduction
16.6.2.2. Market Analysis and Forecast by Market Taxonomy
16.6.2.2.1. By Drug Class
16.6.2.2.2. By Distribution Channel
17. Middle East and Africa (MEA) Polycystic Ovary Syndrome (PCOS) Treatment Market Analysis 2015–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. North Africa
17.3.1.4. South Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Drug Class
17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Distribution Channel
17.5. Drivers and Restraints – Impact Analysis
17.5.1. By Country
17.5.2. By Drug Class
17.5.3. By Distribution Channel
17.6. Country Level Analysis & Forecast
17.6.1. GCC Countries Polycystic Ovary Syndrome (PCOS) Treatment Market
17.6.1.1. Introduction
17.6.1.2. Market Analysis and Forecast by Market Taxonomy
17.6.1.2.1. By Drug Class
17.6.1.2.2. By Distribution Channel
17.6.2. Israel Polycystic Ovary Syndrome (PCOS) Treatment Market
17.6.2.1. Introduction
17.6.2.2. Market Analysis and Forecast by Market Taxonomy
17.6.2.2.1. By Drug Class
17.6.2.2.2. By Distribution Channel
17.6.3. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market
17.6.3.1. Introduction
17.6.3.2. Market Analysis and Forecast by Market Taxonomy
17.6.3.2.1. By Drug Class
17.6.3.2.2. By Distribution Channel
17.6.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market
17.6.4.1. Introduction
17.6.4.2. Market Analysis and Forecast by Market Taxonomy
17.6.4.2.1. By Drug Class
17.6.4.2.2. By Distribution Channel
17.6.5. North Africa Polycystic Ovary Syndrome (PCOS) Treatment Market
17.6.5.1. Introduction
17.6.5.2. Market Analysis and Forecast by Market Taxonomy
17.6.5.2.1. By Drug Class
17.6.5.2.2. By Distribution Channel
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Deep Dive (Tentative List)
18.2.1. Novartis AG
18.2.1.1. Overview
18.2.1.2. Product Portfolio
18.2.1.3. Key Financials
18.2.1.4. SWOT Analysis
18.2.1.5. Sales Footprint
18.2.1.6. Strategy Overview
18.2.1.7. Key Developments
18.2.2. Sanofi.
18.2.2.1. Overview
18.2.2.2. Product Portfolio
18.2.2.3. Key Financials
18.2.2.4. SWOT Analysis
18.2.2.5. Sales Footprint
18.2.2.6. Strategy Overview
18.2.2.7. Key Developments
18.2.3. Teva Pharmaceutical Industries Limited
18.2.3.1. Overview
18.2.3.2. Product Portfolio
18.2.3.3. Key Financials
18.2.3.4. SWOT Analysis
18.2.3.5. Sales Footprint
18.2.3.6. Strategy Overview
18.2.3.7. Key Developments
18.2.4. Merck & Co., Inc. (Merck group)
18.2.4.1. Overview
18.2.4.2. Product Portfolio
18.2.4.3. Key Financials
18.2.4.4. SWOT Analysis
18.2.4.5. Sales Footprint
18.2.4.6. Strategy Overview
18.2.4.7. Key Developments
18.2.5. AstraZeneca plc.
18.2.5.1. Overview
18.2.5.2. Product Portfolio
18.2.5.3. Key Financials
18.2.5.4. SWOT Analysis
18.2.5.5. Sales Footprint
18.2.5.6. Strategy Overview
18.2.5.7. Key Developments
18.2.6. Bayer AG
18.2.6.1. Overview
18.2.6.2. Product Portfolio
18.2.6.3. Key Financials
18.2.6.4. SWOT Analysis
18.2.6.5. Sales Footprint
18.2.6.6. Strategy Overview
18.2.6.7. Key Developments
18.2.7. Abbott
18.2.7.1. Overview
18.2.7.2. Product Portfolio
18.2.7.3. Key Financials
18.2.7.4. SWOT Analysis
18.2.7.5. Sales Footprint
18.2.7.6. Strategy Overview
18.2.7.7. Key Developments
18.2.8. Pfizer, Inc.
18.2.8.1. Overview
18.2.8.2. Product Portfolio
18.2.8.3. Key Financials
18.2.8.4. SWOT Analysis
18.2.8.5. Sales Footprint
18.2.8.6. Strategy Overview
18.2.8.7. Key Developments
18.2.9. Bristol-Myer Squibb Company
18.2.9.1. Overview
18.2.9.2. Product Portfolio
18.2.9.3. Key Financials
18.2.9.4. SWOT Analysis
18.2.9.5. Sales Footprint
18.2.9.6. Strategy Overview
18.2.9.7. Key Developments
18.2.10. Ferring Pharmaceuticals, Inc.
18.2.10.1. Overview
18.2.10.2. Product Portfolio
18.2.10.3. Key Financials
18.2.10.4. SWOT Analysis
18.2.10.5. Sales Footprint
18.2.10.6. Strategy Overview
18.2.10.7. Key Developments
18.2.11. Johnson and Johnson
18.2.11.1. Overview
18.2.11.2. Product Portfolio
18.2.11.3. Key Financials
18.2.11.4. SWOT Analysis
18.2.11.5. Sales Footprint
18.2.11.6. Strategy Overview
18.2.11.7. Key Developments
18.2.12. Mylan N.V.
18.2.12.1. Overview
18.2.12.2. Product Portfolio
18.2.12.3. Key Financials
18.2.12.4. SWOT Analysis
18.2.12.5. Sales Footprint
18.2.12.6. Strategy Overview
18.2.12.7. Key Developments
18.2.13. Allergan plc.
18.2.13.1. Overview
18.2.13.2. Product Portfolio
18.2.13.3. Key Financials
18.2.13.4. SWOT Analysis
18.2.13.5. Sales Footprint
18.2.13.6. Strategy Overview
18.2.13.7. Key Developments
18.2.14. GlaxoSmithKline
18.2.14.1. Overview
18.2.14.2. Product Portfolio
18.2.14.3. Key Financials
18.2.14.4. SWOT Analysis
18.2.14.5. Sales Footprint
18.2.14.6. Strategy Overview
18.2.14.7. Key Developments
18.2.15. Lupin Pharmaceuticals
18.2.15.1. Overview
18.2.15.2. Product Portfolio
18.2.15.3. Key Financials
18.2.15.4. SWOT Analysis
18.2.15.5. Sales Footprint
18.2.15.6. Strategy Overview
18.2.15.7. Key Developments
18.2.16. AbbVie
18.2.16.1. Overview
18.2.16.2. Product Portfolio
18.2.16.3. Key Financials
18.2.16.4. SWOT Analysis
18.2.16.5. Sales Footprint
18.2.16.6. Strategy Overview
18.2.16.7. Key Developments
18.2.17. Takeda
18.2.17.1. Overview
18.2.17.2. Product Portfolio
18.2.17.3. Key Financials
18.2.17.4. SWOT Analysis
18.2.17.5. Sales Footprint
18.2.17.6. Strategy Overview
18.2.17.7. Key Developments
18.2.18. BIOCAD Global
18.2.18.1. Overview
18.2.18.2. Product Portfolio
18.2.18.3. Key Financials
18.2.18.4. SWOT Analysis
18.2.18.5. Sales Footprint
18.2.18.6. Strategy Overview
18.2.18.7. Key Developments
18.2.19. Blairex Laboratories Inc.
18.2.19.1. Overview
18.2.19.2. Product Portfolio
18.2.19.3. Key Financials
18.2.19.4. SWOT Analysis
18.2.19.5. Sales Footprint
18.2.19.6. Strategy Overview
18.2.19.7. Key Developments
18.2.20. Agile Therapeutics
18.2.20.1. Overview
18.2.20.2. Product Portfolio
18.2.20.3. Key Financials
18.2.20.4. SWOT Analysis
18.2.20.5. Sales Footprint
18.2.20.6. Strategy Overview
18.2.20.7. Key Developments